NEW HIGHLIGHT
Firazyr

Firazyr

icatibant

Manufacturer:

Takeda

Distributor:

Zuellig Pharma

Marketer:

Takeda
Concise Prescribing Info
Contents
Icatibant acetate
Indications/Uses
Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents & childn ≥2 yr, w/ C1-esterase-inhibitor deficiency.
Dosage/Direction for Use
SC Adult 30 mg as single dose. Insufficient relief or recurrence of symptoms 2nd inj after 6 hr, then 3rd inj after further 6 hr. Max: 3 inj in 24-hr period or not >8 inj/mth. Adolescents & childn aged 2-17 yr weighing >65 kg 30 mg, 51-65 kg 25 mg, 41-50 kg 20 mg, 26-40 kg 15 mg, 12-25 kg 10 mg. Max: Not >1 inj.
Contraindications
Special Precautions
Patients w/ laryngeal attacks; acute ischemic heart disease or unstable angina pectoris; stroke. May affect ability to drive & use machines. Pregnancy. Not to breastfeed for 12 hr after treatment. Childn <2 yr weighing <12 kg. Elderly >65 yr.
Adverse Reactions
Inj site reactions. Dizziness, headache; nausea; rash, erythema, pruritus; pyrexia; increased transaminases.
Drug Interactions
Possible enhancement of bradykinin levels w/ ACE inhibitors.
MIMS Class
Immunosuppressants
ATC Classification
B06AC02 - icatibant ; Belong to the class of drugs used in the treatment of hereditary angioedema.
Presentation/Packing
Form
Firazyr soln for inj 30 mg/3 mL
Packing/Price
3 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in